Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VY1706 Low dose, VY1706 Mid dose
VY1706 · 1 trial · 1 indication
Incidence of treatment emergent adverse events, clinically significant changes from baseline in vital signs, physical and neurological exams, Columbia Suicide-Severity Rating Scale, Electrocardiogram, Clinical lab parameters and transthoracic echocardiogram
| Arm | Type | Description |
|---|---|---|
| Low dose IV Infusion | EXPERIMENTAL | - |
| Mid dose IV Infusion | EXPERIMENTAL | - |
| High dose IV Infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VY1706 Low dose | DRUG | Low dose |
| VY1706 Mid dose | DRUG | Mid Dose |
| VY1706 High Dose | DRUG | High dose |
| Anti-AAV9 Total Antibody (TAb) Assay | DEVICE | Anti-AAV9 Total Antibody (TAb) Assay |
Inclusion Criteria: * Male or female participants aged 55 to 80 years (inclusive) at Screening or aged 30 to 80 years (inclusive) if presence of a historically documented dominantly inherited mutation associated with monogenic AD. * Clinical diagnosis of mild cognitive impairment (MCI) due to AD or...
Top 20 of 30 competitors
VY1706 is an investigational small molecule being developed by Voyager Therapeutics, Inc. for Alzheimer's disease. It is in Phase 1 clinical development and is designed to act on the MAPT gene, which encodes the tau protein. VY1706 has not been approved by the FDA and remains an experimental therapy under study.
VY1706 is being studied as a treatment for early Alzheimer's disease. The ongoing Phase 1 trial enrolls participants with early Alzheimer's disease, and the drug is given as an open label dose escalation. It is investigational and has not been approved for any indication.
VY1706 targets MAPT, the gene that encodes the tau protein. Tau is a key protein in Alzheimer's disease biology, and targeting MAPT is intended to influence tau production. Voyager Therapeutics is developing VY1706 as a small molecule directed at this target.
VY1706 is being developed by Voyager Therapeutics, Inc., which trades on the Nasdaq under the ticker VYGR. Voyager is the sponsor of the clinical program evaluating VY1706 in early Alzheimer's disease.
VY1706 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program is currently recruiting participants, and no trials of VY1706 have been completed.
VY1706 is being evaluated in one active clinical trial, NCT07764146, titled an open label dose escalation study of VY1706 in participants with early Alzheimer's disease. The Phase 1 study is recruiting in the United States and plans to enroll 18 participants aged 30 years and older.
Yes. VY1706 Low dose and VY1706 Mid dose refer to dose levels of the same investigational drug, VY1706. These labels describe different dose cohorts within the ongoing Phase 1 dose escalation study rather than separate products.